Loading…
Loading…
EQUITY / NASDAQ · XNCM
TuHURA Biosciences, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.94 USD · 1.5707%
Observed: Oct 2, 2026, 9:07 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.91 USD · Volume 287,796
251 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Net income | -9,223,298 USD | -9,523,835 USD | — |
| Cash and cash equivalents | 995,977 USD | — | — |
| Total liabilities | 13,245,793 USD | — | — |
| Total equity | 18,500,460 USD | 19,449,528 USD | -4.88% |
| Total assets | 31,746,253 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 995,977 USD | — | — | 3,619,949 USD | 3,619,949 USD | 2,697,416 USD | — | — |
| Net incomeIncome statement | -9,223,298 USD | -16,759,896 USD | -7,536,598 USD | — | -30,051,977 USD | -7,102,455 USD | -23,290,661 USD | -9,523,835 USD |
| Total assetsBalance sheet | 31,746,253 USD | — | — | 27,353,156 USD | 27,353,156 USD | 25,697,048 USD | — | — |
| Total equityBalance sheet | 18,500,460 USD | — | 23,189,881 USD | 20,932,328 USD | 20,932,328 USD | 16,777,959 USD | — | 19,449,528 USD |
| Total liabilitiesBalance sheet | 13,245,793 USD | — | — | 6,420,828 USD | 6,420,828 USD | 8,919,089 USD | — | — |
| Capital expendituresCash flow statement | — | 185,824 USD | — | — | 76,083 USD | — | 48,233 USD | — |
| Financing cash flowCash flow statement | — | 10,608,404 USD | — | — | 19,927,282 USD | — | 13,420,877 USD | — |
| Investing cash flowCash flow statement | — | -185,824 USD | — | — | -1,335,361 USD | — | -1,307,511 USD | — |
| Operating cash flowCash flow statement | — | -13,046,552 USD | — | — | -27,629,150 USD | — | -22,073,128 USD | — |
| RevenueIncome statement | — | — | — | — | 0 USD | — | 0 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.